Cyclosporin H NEW
| Price | $125 | $278 | $392 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-09 |
Product Details
| Product Name: Cyclosporin H | CAS No.: 83602-39-5 |
| Purity: 99.94% | Supply Ability: 10g |
| Release date: 2025/07/09 |
Product Introduction
Bioactivity
| Name | Cyclosporin H |
| Description | Cyclosporin H (CsH), a specific inhibitor of FPR1, inhibited lung inflammation in the ALI models. CsH significantly attenuated MTDs or NFP-induced inflammatory lung injury and activation of MAPK and AKT pathways. Cyclosporin H is a viral transduction enhancer which increases lentiviral transduction up to 10-fold in human cord blood-derived hematopoietic stem and progenitor cells (HSPCs). When combined with Rapamycin or Prostaglandin E2 Cyclosporin H displays an additive effect. Cyclosporin H lacks immunosuppressant activity of Cyclosporin A. |
| In vitro | Cyclosporin H is a potent inhibitor of FMLP-induced superoxide anion (O2-) formation in human neutrophils. Cyclosporin H inhibited FMLP binding in HL-60 membranes with a Ki (inhibition constant) of 0.10 μM. Cyclosporin H inhibited activation by FMLP of high affinity GTPase (the enzymatic activity of alpha-subunits of heterotrimeric regulatory guanine nucleotide-binding proteins) in HL-60 membranes with a Ki of 0.79 μM. Cyclosporin H inhibited the stimulatory effects of FMLP on cytosolic Ca2+ concentration ([Ca2+]i), O2- formation, and beta-glucuronidase release with Ki values of 0.08, 0.24, and 0.45 μM, respectively. |
| In vivo | Cyclosporin H, administered intraperitoneally (i.p.) at a dosage of 5 mg/kg prior to challenge with LPS or HCl, mitigates lung injury caused by LPS or HCl in a lung injury model. |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 99 mg/mL (82.32 mM), Sonication is recommended. |
| Keywords | viral | transduction | lentiviral | Inhibitor | inhibit | FPR1 | Cyclosporin H |
| Related Compound Libraries | Cyclic Peptide Library | Peptide Compound Library | Anti-Viral Compound Library | Anti-Infection Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $999.00/5kg |
VIP1Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2024-08-20 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2025-04-17 | |
| $0.00/10mg |
VIP1Y
|
Moxin Chemicals
|
2025-01-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY